Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

638P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Preliminary findings from a single-arm, prospective phase II trial (RIFLE)

Date

21 Oct 2023

Session

Poster session 11

Topics

Targeted Therapy;  Immunotherapy;  Radiation Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

Yajiie Chen

Citation

Annals of Oncology (2023) 34 (suppl_2): S410-S457. 10.1016/S0923-7534(23)01935-X

Authors

Y. Chen1, K. Wang1, Z. Zhiyuan2, H. Zhang1, W. Yang1, R. Wu1, M. Zhou1, Z. Zhang3, F. Xia1

Author affiliations

  • 1 Department Of Radiation Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 2 Department Of Radiation Therapy, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN
  • 3 Radiation Oncology, Fudan University Shanghai Cancer Center, 200032 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 638P

Background

Stereotactic ablative radiotherapy (SABR) has been shown to sensitize immunotherapy through inducing immunogenic death and remodeling the tumor immune microenvironment. Anti-angiogenic therapy exhibits synergistic antitumor effects with PD-1/PD-L1 antibodies through its immunomodulatory effects for ≥ 3L metastatic colorectal cancer (mCRC) patients. Here, we report the preliminary results from RIFLE trial: the efficacy and safety of the combination of fruquintinib, PD-1 inhibitor tislelizumab and SABR in mCRC patients.

Methods

This is a single-center, single-arm, prospective phase II clinical trial (NCT04948034). mCRC patients with at least 2 measurable lesions who have failed ≥ 1L standard therapy will receive SABR followed by fruquintinib (5 mg, d1-14, qd) and tislelizumab (200 mg, d1, q3w) within two weeks from completion of radiation. The primary endpoint is the objective response rate (ORR). The secondary endpoints include disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) rate, overall survival (OS) rate and toxicity.

Results

From August 2021 to April 2023, 27 patients were included in the trial and 24 in the efficacy analysis. Median age was 64 years, 17 (70.8%) patients were male, 21(87.5%) had ≥ 3 metastases, and 12(50%) had received ≥ 3 prior lines of systemic therapy. The biological effective dose (BED) for irradiated lesions ranged from 37.5 to 105 Gy. Median study follow-up was 12.6 months, 20 patients were alive and 11 remained on treatment. 7 patients achieved partial response (PR) for target lesions, 10 stable disease (SD), illustrating an ORR of 29.2% and a DCR of 70.8%. Median PFS was not reached. The most common treatment-related adverse events (TRAEs) were proteinuria (45.8%), hypertension (25%) and rash (16.7%). Grade 3-4 AEs occurred in 8 patients, including proteinuria and hypertension, and there were no treatment-related deaths.

Conclusions

SABR combined with tislelizumab and fruquintinib shows promising effects and good safety in the treatment of metastatic colorectal cancer, which is expected to provide new therapeutic strategies and improve the prognosis for mCRC patients.

Clinical trial identification

NCT04948034.

Editorial acknowledgement

Legal entity responsible for the study

Fudan University Shanghai Cancer Center.

Funding

Hutchison MediPharma Co., Ltd. and BeiGene (Beijing) Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.